United States Federal Circuit
Gilead Sciences, Inc. v. Merck & Co., Inc., 16-2302
Affirming the judgment that Merck, initially defending its patent on Hepatitis C drugs against a competitor seeking to have them found invalid, who successfully counter-sued for infringement, had unclean hands regarding the patents and was properly barred from asserting its patents and awarded attorney fees to the plaintiff.
Appellate Information
- Published 2018/04/25
Judges
- TARANTO
Court
- United States Federal Circuit